Drug Development Pipeline
Restore CFTR Function
This program is working to expand the number of therapies designed to fix the defective CFTR protein in people who have the F508del mutation.
Laboratory studies to develop and test these compounds are underway.
This program is sponsored by Reata Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More